Denosumab News and Research

RSS
Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone.
Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen's Prolia receives FDA approval for new indications to treat cancer patients

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen to present data from several Prolia studies at ASBMR 2011 meeting

Amgen reports 8% increase in second quarter total product sales to $3,893 million

Amgen reports 8% increase in second quarter total product sales to $3,893 million

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

EC grants marketing authorization for Amgen's XGEVA to prevent skeletal-related events

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

EMA CHMP recommends positive opinion for marketing authorization of Amgen's XGEVA

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Quebec provides access to new treatment for women with postmenopausal osteoporosis

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Amgen wins Scrip Best New Drug award for Prolia

Amgen wins Scrip Best New Drug award for Prolia

Amgen reports $3,816 million for 2010 third quarter revenue

Amgen reports $3,816 million for 2010 third quarter revenue

Amgen to present oncology portfolio results at ESMO Congress

Amgen to present oncology portfolio results at ESMO Congress

HRT therapy can increase breast cancer risk

HRT therapy can increase breast cancer risk